 |
| Vical Incorporated |
Last news on Vical Inc ( NASDAQ: VICL ) was on 14th april 2011 about European Patent for CMV ( Cytomegalovirus ) Vaccine and it will conduct Phase III clinical trials in second half of 2011 and also it was given a buy rating today by Canaccord Genuity.
Vical Incorporated announced the issuance of European Patent EP1587816, which extends coverage for TransVax, the Company's therapeutic DNA vaccine designed to prevent reactivation of latent cytomegalovirus (CMV) or introduction of CMV through donor cells or tissues in transplant recipients. TransVax encodes the CMV glycoprotein B (gB) and phosphoprotein 65 (pp65) antigens, and is formulated with a poloxamer designed to enhance primarily a cellular immune response. Vical's TransVax vaccine has orphan drug designation for transplant patients. In September 2010, Vical announced encouraging results from a completed Phase 2 trial of the TransVax vaccine in patients undergoing hematopoietic stem cell transplants
Past development by others of protein-based prophylactic CMV vaccines has focused on antibody-mediated immune responses against the CMV gB antigen, which has achieved up to 50% protective efficacy. The new '816 patent covers DNA vaccines containing codon-optimized versions of genes encoding gB and CMV pp65 antigens, formulated with the CRL-1005 poloxamer in-licensed by Vical. It adds to Vical's family of patents in key geographic regions based on the company's discovery that administering genetic sequences such as DNA or RNA into the body, without the use of viral delivery vehicles, may cause expression of the proteins encoded by the genetic sequences. Vical has additional issued patents covering enhancements, manufacturing, and specific applications of its core technology.( Source: Vical Incorporated )
Vical Incorporated has received a US patent for the same vaccine in early february. Choose from links here
Based on continuous news flow about its vaccine product and its patent, stock has started an uptrend. It might cross 52 week range and trade at new 52 week high if any news in development. People familiar with the development have started taking their position. Keep a track on the stock and stay tuned about any news of the company.
0 comments